<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CAR-NKT cell therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/car-nkt-cell-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 22 Oct 2025 19:35:58 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CAR-NKT cell therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>UCLA Researchers Create Universal Single-Product Immunotherapy for Breast Cancer</title>
		<link>https://bioengineer.org/ucla-researchers-create-universal-single-product-immunotherapy-for-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 19:35:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-NKT cell therapy]]></category>
		<category><![CDATA[mesothelin-targeted therapy]]></category>
		<category><![CDATA[off-the-shelf cellular therapy]]></category>
		<category><![CDATA[triple-negative breast cancer]]></category>
		<category><![CDATA[triple-negative breast cancer treatment]]></category>
		<category><![CDATA[UCLA cancer research]]></category>
		<category><![CDATA[universal immunotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ucla-researchers-create-universal-single-product-immunotherapy-for-breast-cancer/</guid>

					<description><![CDATA[Triple-negative breast cancer (TNBC) has long posed a formidable challenge within oncology, notorious for its aggressive nature and limited treatment avenues. Unlike other breast cancer subtypes, TNBC lacks expression of estrogen receptors, progesterone receptors, and HER2 proteins, which have traditionally served as therapeutic targets for more personalized and effective treatment regimens. This absence of molecular [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">285388</post-id>	</item>
	</channel>
</rss>
